Hollis Eden Pharmaceuticals Inc. (HEPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Hollis Eden Pharmaceuticals Inc. (HEPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jim Oravetz who wrote (117)	10/12/2000 12:57:42 PM
From: Jim Oravetz	Read Replies (1) of 138

Hollis-Eden Buys Stake In Aeson Therapeutics Dow Jones Newswires SAN DIEGO -- Hollis-Eden Pharmaceuticals Inc. (HEPH) paid $2 million for 208,681 shares, or 21%, of Aeson Therapeutics Inc., Tuscon, Ariz. Hollis-Eden was also granted the right to acquire the remainder of Aeson at a predetermined price at any time over the next 30 months. In a press release Thursday, Hollis-Eden said it also obtained an exclusive sublicense to three additional patents concerning adrenal steroids from Aeson. These intellectual property rights are being leased to Aeson by Research Corporation Technologies Inc. Hollis-Eden said Aeson is developing molecules that are analogs with similar biological properties to HE2000, Hollis-Eden's primary compound in development. Aeson's lead compound, fluasterone, is in Phase II clinical trials. Aeson will use the cash from the sale of shares to fund studies with fluasterone as well as other compounds under development. Shares of Hollis-Eden recently traded at $7.38, down 25 cents, or 3.3% on Nasdaq volume of 7,900 shares. Average daily volume is 37,411. Jim

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next